SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending after reporting robust earnings, driven by significant revenue growth and an improving path to profitability as its AI infrastructure expands. The community is actively discussing the company's substantial pipeline of new data center capacity, including advanced negotiations for 900MW across multiple hyperscale sites, anticipating strong long-term growth. This aggressive expansion into high-performance computing is fueling speculation about potential short-covering activity and a re-rating of the stock within the booming AI sector.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is gaining significant attention after experiencing a substantial price surge on massive trading volume, which has triggered a technical breakout and suggests strong altcoin rotation. The community is actively discussing the potential for Jasmy to push past the one-cent threshold, fueled by anticipation of major 2026 developments focused on decentralized AI, data monetization, and its regulatory standing in Japan. While some voice skepticism about past volatility, many investors are highlighting its foundational utility in IoT and secure data, along with its ex-Sony leadership, as key drivers for future growth.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following positive FDA feedback indicating its existing data is sufficient for a Biologics License Application for sonelokimab in hidradenitis suppurativa, significantly de-risking its path to market. This clarity has ignited strong community discussion, highlighting the stock as undervalued and a prime buyout candidate, with many speculating on Merck's renewed interest and the potential for a substantial short squeeze.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing a notable multi-day decline, leading to discussions among the community about its deeply oversold technicals and a perceived lack of an immediate AI narrative compared to peers like Alphabet, which recently surpassed its market cap. While some express concern over the persistent weakness, many are actively buying the dip, anticipating a rebound and potential short squeeze dynamics fueled by unverified rumors of high synthetic short interest.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending due to sharp stock price volatility following preliminary Q4 results and future revenue guidance that projected a decline in DefenCath sales. While many investors express frustration and accuse management of mishandling expectations, a significant portion of the community sees the downturn as an overreaction, emphasizing the strong Q4 financial performance, the diversified pipeline from the Melinta acquisition, and compelling positive real-world data for DefenCath.

flyExclusive, Inc. engages in owning and operating jet aircraft for private jet passengers. It manages all aspects of the customer experience, in-house maintenance, repair, and overhaul services, including paint, interiors, and avionics capabilities. The company was founded by Thomas James Segrave, Jr. in 2015 and is headquartered in Kinston, NC.

flyExclusive Inc. - Ordinary Shares - Class A

flyExclusive (FLYX) is soaring amid news of its authorized dealership agreement with Starlink, positioning the company as an installer of high-speed in-flight internet for private jets and opening new MRO revenue opportunities. The community is actively discussing the potential for a massive short squeeze, driven by the stock's reportedly low float and explosive trading volume. Traders are eyeing significant upside, fueled by optimism around the SpaceX connection and comparisons to previous high-flying tickers.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is trending due to significant attention on the robotics sector, highlighted by Nvidia's CEO mentioning Serve as a key part of the "Physical AI" ecosystem and reports of potential government initiatives to boost the industry. This comes as the company achieves a major milestone with over 2,000 deployed autonomous delivery robots and strengthens partnerships, leading to community discussions about its market leadership and short-squeeze potential.

iPower, Inc. engages in the online retail and supply of consumer home, garden, in-home farming, pet, and wellbeing products. It sells its brands such as Simple Deluxe, YSSOA, Zenhydro, Flourish, iPOWER, iFarm, FluffyDream, ScratchMe, and HealSmart through zenhydro.com, simpledeluxe.com, and various third-party online platforms. The company offers grow light systems, advanced heating, ventilation and air conditioning (HVAC) systems, water pumps, heaters, chillers and filters, nutrient and fertilizer delivery systems, and various growing media typically made from soil, rock wool or coconut fiber. It also provides home goods supplies including commercial fans, floor and wall fans, storage and shelving units, and chairs. The company was founded by Chenlong Tan and Allan Huang on April 11, 2018 and is headquartered in Rancho Cucamonga, CA.

iPower Inc

iPower Inc. is a major trending topic, driven by its exceptionally low public float that has sparked significant community discussion about a potential short squeeze, drawing comparisons to other high-volatility movers. Further fueling the conversation are the company's recent strategic moves, including initial investments into digital assets and announcements regarding debt repayment. The narrative is currently polarized between those anticipating substantial price action and others who remain cautious of rapid speculative movements.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. is trending after providing an update on its accelerating AI back pain platform, Nociscan, reporting substantial scan volume growth and a robust, debt-free balance sheet with an extended cash runway. The community is buzzing about the stock's extremely low float and significant cash per share, fueling speculation for a potential short squeeze and considerable upward price movement. Traders are actively accumulating shares, anticipating a notable revaluation, despite some ongoing calls of manipulation.

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Mind Medicine Inc

Mind Medicine Inc - Ordinary Shares (Sub Voting)

MindMed is seeing heightened discussion following a new 'Buy' rating from Jones Trading that included a high price target, fueling widespread community speculation about an impending acquisition. This momentum is further driven by the recent publication of positive MM120 (LSD) trial results for Generalized Anxiety Disorder in JAMA, signaling significant progress in the emerging psychedelic therapeutics sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: OptimizeRx (NASDAQ:OPRX) Insider Sells 1,388 Shares of Stock

OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) insider Edward Stelmakh sold 1,388 shares of the firm's stock in a transaction that occurred on Friday, December 19th. The stock was sold at an...

OptimizeRx (NASDAQ:OPRX) Insider Sells $18,751.88 in Stock

OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) insider Edward Stelmakh sold 1,388 shares of the business's stock in a transaction dated Friday, December 19th. The stock was sold at an average price...

OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eleven ratings firms that are presently covering the firm, MarketBeat.com reports. One...

OptimizeRx (NASDAQ:OPRX) Cut to "Hold" at Zacks Research

Zacks Research lowered shares of OptimizeRx from a "strong-buy" rating to a "hold" rating in a report on Monday...

Wall Street Zen Upgrades OptimizeRx (NASDAQ:OPRX) to "Strong-Buy"

Wall Street Zen raised OptimizeRx from a "buy" rating to a "strong-buy" rating in a research note on Sunday...

OptimizeRx (NASDAQ:OPRX) Cut to "Buy" at Wall Street Zen

Wall Street Zen downgraded OptimizeRx from a "strong-buy" rating to a "buy" rating in a research report on Saturday...

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in OptimizeRx Corp. $OPRX

Connor Clark & Lunn Investment Management Ltd. bought a new stake in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) in the second quarter, according to its most recent filing with the Securities...

P.A.W. Capital Corp Invests $675,000 in OptimizeRx Corp. $OPRX

P.A.W. Capital Corp purchased a new position in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and...

New Strong Buy Stocks for Nov. 17: ROKU, AVPT, and More

ROKU, AVPT, ETOR, NRIM and OPRX have been added to the Zacks Rank #1 (Strong Buy) List on November 17, 2025.

Los Angeles Capital Management LLC Makes New $349,000 Investment in OptimizeRx Corp. $OPRX

Los Angeles Capital Management LLC purchased a new stake in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The...

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.

OptimizeRx Corp

SpaceX

Discord

OpenAI

Other - Comment Below

A few major private companies are being discussed as potential IPO candidates in 2026 — including SpaceX, Discord, Databricks, OpenAI, Anthropic, and Deel. IPO timelines can shift, but if one of these listings happens this year, which are you most excited to watch?

Which Potential 2026 IPO Are You Most Excited For?

OPRX
OptimizeRx Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OPRX News

OPRXOptimizeRx Corp